Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NCT02648724 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Oncology
MET Gene Amplification
NSCLC
MET Gene Mutation
Non Small Cell Lung Cancer

Interventions

DRUG: Sym015

Sponsor

Symphogen A/S